Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 17/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1880413 | 0.93 | IGF1R (0.54) | IGF1RNAMPT | |
| SCHEMBL1882936 | 0.93 | IGF1R (0.54) | IGF1R | |
| SCHEMBL1881116 | 0.92 | IGF1R (0.53) | IGF1RNAMPT | |
| SCHEMBL1875715 | 0.89 | IGF1R (0.53) | IGF1RMAPK1 | |
| SCHEMBL4111784 | 0.88 | IGF1R (0.69) | IGF1RMAPK1 | |
| SCHEMBL1879534 | 0.88 | IGF1R (0.52) | IGF1R | |
| SCHEMBL1879419 | 0.86 | IGF1R (0.56) | IGF1R | |
| SCHEMBL1883947 | 0.85 | IGF1R (0.57) | IGF1R | |
| SCHEMBL1882582 | 0.84 | IGF1R (0.56) | IGF1RMAPK1 | |
| SCHEMBL1888563 | 0.84 | IGF1R (0.55) | IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979339-B1 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2012-10-31 | — | — | EP | disclosed |
| US-7935819-B2 | Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2011-05-03 | — | — | US | disclosed |
| US-20090082379-A1 | Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082379-A1 | Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | PRKAR2B, CDK1, PRKX | IGF1R 962/4885MAPK1 49/4885NAMPT 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.